The FDA has assigned a goal date of Aug.13, 2024, for Lymphir to treat patients with relapsed or refractory cutaneous T-cell lymphoma.
The FDA has accepted the resubmission of the Citius Pharmaceuticals’ biologics license application (BLA) for Lymphir (denileukin diftitox), to treat patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The FDA has assigned a Prescription Drug User Fee Act goal date of Aug.13, 2024.
Cutaneous T-cell lymphoma is a type of cutaneous non-Hodgkin lymphoma (NHL), accounting for about 4% of all non-Hodgkin lymphoma, according to the American Cancer Society. In cutaneous T-cell lymphoma, T-cells, a type of lymphocyte that plays a role in the immune system, become cancerous and presents as red, scaly patches on the skin. It is more common among men than women, with an average age of onset between 50 and 60 years of age. It is generally a slow-growing cancer but in rare cases can spread to lymph nodes and internal organs.
Lymphir (previously called I/Ontak) is a recombinant fusion protein that combines interleukin-2 (IL-2) receptors with diphtheria toxin fragments. It binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis.
The FDA had issued a complete response letter in July 2023, and the agency asked Citius to do enhanced product testing. The company said in a press release that it believes it has addressed enhanced product testing and additional manufacturing controls noted in the letter. There were no safety or efficacy issues cited and no additional trials required.
Ontak was marketed in the United States from 1999 to 2014, when it was voluntarily withdrawn from the market because of production issues related to the E. coli expression system and purification challenges. Citius official have said that manufacturing improvements resulted in a new formulation that maintains the same amino acid sequence but features improved purity and bioactivity.
The BLA is supported by a pivotal phase 3 study. The therapy demonstrated anti-tumor activity in the treatment of persistent or recurrent CTCL. It provided disease control and has an average time to response within one to two cycles of treatment in patients who have failed multiple prior therapies. An independent review committee determined the study achieved an objective response rate of 36.2% and an investigator efficacy analysis determined that the study achieved an objective response rate of 42.3%. Most common adverse events included: nausea, fatigue, increased alanine aminotransferase, chills and peripheral edema.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More